Skip to content
Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma

Adjuvant Checkpoint Inhibition Extends Disease-Free and Overall Survival in Patients with Stage III Melanoma

Get the podcast

COPENHAGEN, Denmark—Checkpoint inhibition prolonged life when used as adjuvant therapy among patients with fully resected stage III malignant melanoma in the EORTC 18071 randomized phase III compariso

The Audio Journal of Oncology

COPENHAGEN, Denmark—Checkpoint inhibition prolonged life when used as adjuvant therapy among patients with fully resected stage III malignant melanoma in the EORTC 18071 randomized phase III comparison of ipilimumab versus placebo. Findings were reported by Alexander M.M. Eggermont, M.D., Ph.D., Director General of the Comprehensive Cancer Center, Institut Gustave Roussy in Paris at the 2016 congress of the European Society for Medical Oncology—ESMO. He discusses his findings with the Audio Journal of Oncology’s Peter Goodwin.

Adjuvant Ipilimumab Brings Longer Survival with Stage III Melanoma

COPENHAGEN, Denmark—Checkpoint inhibition prolonged life, increased recurrence free survival and delayed metastasis when used as adjuvant therapy in patients who had fully resected stage III (regional lymph-node positive) malignant melanoma in the European Organization for Research and Treatment of Cancer (EORTC) 18071 randomized phase 3 comparison of ipilimumab versus placebo. Findings were reported at the 2016 congress of the European Society for Medical Oncology (ESMO). http://www.nejm.org/doi/full/10.1056/NEJMoa1611299?rss=searchAndBrowse#t=articleTop

The study found a 28 percent risk reduction for death in patients treated with ipilimumab, the fully human antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) and enables the patient’s antitumor response.

“This is the first adjuvant study that has been done with an immune checkpoint inhibitor,” said first author Alexander M.M. Eggermont, MD, PhD, Director General of the Comprehensive Cancer Center at the Institut Gustave Roussy in Paris, who noted that previous data about the benefits of ipilimumab in melanoma had come from studies among patients with metastatic disease, among whom around 20 percent had been cured and were alive five to 10 years after beginning treatment.

In the EORTC 18071 study 951 patients from 99 centers in 19 countries were randomized to receive either ipilimumab at a high dose—10 milligrams per kilogram—every three weeks for the first 12 weeks (standard for metastatic disease) followed by one dose every 12 weeks for following three years. Patients in the control arm of the study received the same dosing, but with placebo. The primary endpoint was disease-free survival with overall survival and metastasis-free survival among the secondary endpoints.

All patients had regional lymph node metastatic disease and had undergone lymph node dissection, were tumor-free and were randomized within 12 weeks of their surgery.

Among the 471 patients treated with ipilimumab 251 (53.3 percent) discontinued treatment because of an adverse event as compared with only 22 patients (4.6 percent) in the placebo arm.

But ipilimumab was clearly effective with only 135 patients (28.7 percent) having recurrent disease within the follow-up period as compared with more than double this number, 282 (59.9 percent) of patients treated with placebo.

Only 63 patients (13.4 percent) treated with ipilimumab completed the full three year protocol as compared with 143 (30.2 percent) in the control arm.

“The data coming out of it—in terms of the primary endpoint recurrence-free survival— are significant,” Eggermont said. 40.8% of patients in the ipilimumab group remained free of recurrence five years after randomization compared with 30.3% in the placebo group—a hazard ratio for recurrence or death of 0.76 (P<0.001). “That means there is a 24 percent risk-reduction for [the composite of] relapse or death. So that’s highly significant,” he said.

For death alone adjuvant checkpoint inhibition brought an even bigger improvement. At 5.3 years follow-up the hazard ratio was 0.72 favoring ipilimumab treatment. “That means, in other words, a 28 percent risk-reduction for death,” he said. 162 patients had died in the ipilimumab arm but there were 52 more deaths in the placebo arm.

“So 65 percent of patients [were] still alive who had received ipilimumab, and only 54 percent—or 11 percent less—who had received placebo,” Eggermont said—evidence that checkpoint inhibition brought additional benefit when used earlier—before metastasis—although there were more immune-related adverse events.

Toxicity

But he said that there were grade 3 and 4 immune-related adverse events to which clinicians need to pay special attention. “Toxicities at the gastrointestinal level: diarrhea and full-blown colitis—which can lead to complications and perforations [from] which you can die—[were] seen in 16 percent of patients,” he said. And thyroiditis and hypothyroiditis were among the serious immune-related endocrine grade 3, 4 events. But he said the most important toxicity was knockout of the pituitary gland—hypophysitis, with affected nearly five percent of patients. “What that means is that you are on long-term—even life-long—hormone replacement therapy,” he said.

Additionally there was a 16 percent rate of hepatitis grade 3, 4 events, and he said that two patients had the neurologic immune-related adverse event— Guillain-Barre syndrome, of whom one was on a ventilator for so long that he developed multi-organ failure.

Eggermont said there were also five drug-related deaths on the trial. Three were in patients with colitis, one in a patient with myocarditis, and one more in the patient with Guillain-Barre syndrome.

“So you must instruct patients very carefully, and have a very careful surveillance systems so that you can see [toxicities] early—especially diarrhea and colitis,” he said, when ipilimumab should be stopped and treatments such as high-dose corticosteroids begun.

“And so we plea in favor of centralizing this adjuvant therapy to centers with sufficient experience and infrastructure to survey and instruct the patients to be proactive.”

He noted that using ipilimumab would be done within the large centers that have built up the experience. “I don’t think it’s a great idea that just anybody can prescribe ipilimumab and then fail in the follow-up of these patients.”

Eggermont’s report was discussed at the ESMO congress session by Olivier Michielin MD PhD, Head of the Melanoma Clinic in the Department of Oncology at Lausanne University in Switzerland, who is also Group Leader of the Swiss Institute of Bioinformatics in Lusanne, who said that this new EORTC study had contributed two important lessons, the first of which was clinical. “The benefit of CTLA4 blockade in the metastatic setting is indeed translating into the adjuvant [setting] and the sub-group analysis teaches us a lot about the specificities of ipilimumab compared to interferon,” he said.

Michielin was also impressed by the findings about immunological mechanisms. “Clearly we see for the first time that we can raise a T-cell response in a setting where there is only residual disease to trigger the right antigens. The final analysis shows that checkpoint blockade is effective in the adjuvant setting—a new historical landmark in our quest for the optimal treatment of melanoma.”

He said side effects were all important, which is why he emphasized the need to refer patients with melanoma to centers of excellence. But he pointed out that the therapeutic margin of ipilimumab was favorable compared to many other current treatments in cancer.

But Eggermont said the benefit from ipilimumab, albeit in the context of high toxicity, was a foretaste of what could lie ahead with the use of second-generation checkpoint inhibitors.

“We just fully accrued the trial of adjuvant pembrolizumab, the anti-PD1 drug. And we will be able to do the first analysis in 2018,” he said, adding that the advantage of harnessing anti-PD1 was that the toxicity profile was much more favorable, and yet the response rates—measured so far in metastatic disease—were higher.

While he acknowledged that the durability of therapeutic benefit from this anti-PD1 agents had yet to be assessed he was hopeful. “Expectations are that this is a very attractive adjuvant therapeutic, just like nivolumab, which is the other anti-PD1 agent,” he said. He was looking forward to trial results by the end of 2018.

The EORTC 18071 study with ipilimumab had established a clear superiority to interferon both in categories of patients who have microscopic disease only and in patients with palpable nodal disease, which he contrasted to the previous era. “In our experience—in some 3,000 melanoma patients—we have never seen any impact in palpable nodal disease with adjuvant interferons.

More from ESMO 2016

All 9 interviews

This is the last of the 9 ESMO 2016 interviews. See them all.

Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

12 Nov 2026
4 min
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

5 Nov 2026
10 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.

2 Nov 2026
15 min